Chinese Journal of Tissue Engineering Research ›› 2010, Vol. 14 ›› Issue (10): 1817-1820.doi: 10.3969/j.issn.1673-8225.2010.10.022

Previous Articles     Next Articles

Effect of Astragaloside IV on hematopoietic growth factor expression in rat bone marrow mesenchymal stem cells

Tan Yan-fang1, Yin Xiao-cheng1, Xiong Yu-juan2, Wang Yan1   

  1. 1Department of Pediatrics, First Hospital Affiliated to University of South China, Hengyang   421001, Hunan Province, China;
    2Department of Rehabilitation, Hunan Children’s Hospital, Changsha   410000, Hunan Province, China
  • Online:2010-03-05 Published:2010-03-05
  • Contact: Yin Xiao-cheng, Master, Associate chief physician, Master’s supervisor, Department of Pediatrics, First Hospital Affiliated to University of South China, Hengyang 421001, Hunan Province, China xcyin108@sina.com
  • About author:Tan Yan-fang, Studying for master’s degree, Physician, Department of Pediatrics, First Hospital Affiliated to University of South China, Hengyang 421001, Hunan Province, China 23289616@qq.com

PDF

486

Abstract:

BACKGROUND: Astragaloside IV is a major component of Huangqi, promoting proliferation and differentiation of bone marrow mesenchymal stem cells; however, the mechanism has been less reported yet.

OBJECTIVE: To explore the effect of Astragaloside IV on expression of multiple hematopoietic growth factors in bone marrow mesenchymal stem cells.

METHODS: Bone marrow mesenchymal stem cells were isolated from adult Wistar rats by using the method of adhesive culture and clone, and they were then plated on 96-well plate and separately incubated with 100 μL Astragaloside IV (25, 50, 100, 200 g/L) for 72 hours. The cells in the control group were cultured with an equal volume of DMEM-LG culture liuquid. Indirect immunofluorescence was used to detect the biological activity, MTT method was used to evaluate the effect of Astragaloside IV on proliferation and differentiation of bone marrow mesenchymal stem cells, and RT-PCR method was used to measure the expression of hematopoietic growth factors in bone marrow mesenchymal stem cells.

RESULTS AND CONCLUSION: The 3rd-passage bone marrow mesenchymal stem cells highly expressed CD44 but lowly expressed CD45. As compared with control group, Astragaloside IV promoted proliferation of bone marrow mesenchymal stem cells in a time/dosage-dependent manner, in particular, the 200 g/L Astragaloside IV and 72-hour intervention (P < 0.05). SCF expression was significantly increased in the drug group compared with control group (P < 0.01); however, TPO, GM-CSF, and TGF-β1 expressions were not changed significantly (P > 0.05). Moreover, interleukin-3 expression was not found in the bone marrow mesenchymal stem cells. Astragaloside IV promoted in vitro proliferation of bone marrow mesenchymal stem cells, possibly involving in SCF secretion.

CLC Number: